These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 28652741

  • 1. Determination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC-colistin.
    Sans-Serramitjana E, Jorba M, Pedraz JL, Vinuesa T, Viñas M.
    Int J Nanomedicine; 2017; 12():4409-4413. PubMed ID: 28652741
    [Abstract] [Full Text] [Related]

  • 2. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
    Sans-Serramitjana E, Fusté E, Martínez-Garriga B, Merlos A, Pastor M, Pedraz JL, Esquisabel A, Bachiller D, Vinuesa T, Viñas M.
    J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
    [Abstract] [Full Text] [Related]

  • 3. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W, Green K, Pressler T, Skov M, Katzenstein TL, Wu X, Høiby N.
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [Abstract] [Full Text] [Related]

  • 4. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Pastor M, Moreno-Sastre M, Esquisabel A, Sans E, Viñas M, Bachiller D, Asensio VJ, Pozo AD, Gainza E, Pedraz JL.
    Int J Pharm; 2014 Dec 30; 477(1-2):485-94. PubMed ID: 25445528
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.
    Pompilio A, Crocetta V, Pomponio S, Fiscarelli E, Di Bonaventura G.
    Diagn Microbiol Infect Dis; 2015 Aug 30; 82(4):318-25. PubMed ID: 26004353
    [Abstract] [Full Text] [Related]

  • 6. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
    Pritchard MF, Powell LC, Jack AA, Powell K, Beck K, Florance H, Forton J, Rye PD, Dessen A, Hill KE, Thomas DW.
    Antimicrob Agents Chemother; 2017 Sep 30; 61(9):. PubMed ID: 28630204
    [Abstract] [Full Text] [Related]

  • 7. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
    Kolpen M, Appeldorff CF, Brandt S, Mousavi N, Kragh KN, Aydogan S, Uppal HA, Bjarnsholt T, Ciofu O, Høiby N, Jensen PØ.
    Pathog Dis; 2016 Feb 30; 74(1):ftv086. PubMed ID: 26458402
    [Abstract] [Full Text] [Related]

  • 8. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.
    J Infect Dis; 2010 Nov 15; 202(10):1585-92. PubMed ID: 20942647
    [Abstract] [Full Text] [Related]

  • 9. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A, Lajoie B, El Hage S, Baziard G, Roques C.
    Antimicrob Agents Chemother; 2015 Dec 28; 60(3):1676-86. PubMed ID: 26711774
    [Abstract] [Full Text] [Related]

  • 10. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J, Murillo O, Bergen PJ, Nation RL, Poudyal A, Luo X, Yu HY, Ariza J, Li J.
    J Antimicrob Chemother; 2014 Sep 28; 69(9):2434-42. PubMed ID: 24833752
    [Abstract] [Full Text] [Related]

  • 11. Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa.
    Sweeney E, Sabnis A, Edwards AM, Harrison F.
    Microbiology (Reading); 2020 Dec 28; 166(12):1171-1180. PubMed ID: 33253080
    [Abstract] [Full Text] [Related]

  • 12. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Gómez-Junyent J, Murillo O, Yu HH, Azad MAK, Wickremasinghe H, Rigo-Bonnin R, Benavent E, Ariza J, Li J.
    Int J Antimicrob Agents; 2021 Feb 28; 57(2):106246. PubMed ID: 33253904
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC).
    Vairo C, Basas J, Pastor M, Palau M, Gomis X, Almirante B, Gainza E, Hernandez RM, Igartua M, Gavaldà J, Gainza G.
    Nanomedicine; 2020 Oct 28; 29():102259. PubMed ID: 32619707
    [Abstract] [Full Text] [Related]

  • 14. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
    Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N.
    Antimicrob Agents Chemother; 2012 May 28; 56(5):2683-90. PubMed ID: 22354300
    [Abstract] [Full Text] [Related]

  • 15. Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung.
    Harrington NE, Sweeney E, Alav I, Allen F, Moat J, Harrison F.
    J Vis Exp; 2021 Jan 22; (167):. PubMed ID: 33554970
    [Abstract] [Full Text] [Related]

  • 16. In-vitro bactericidal activity of colistin against biofilm-associated Pseudomonas aeruginosa and Acinetobacter baumannii.
    Cai Y, Wang R, Liang BB, An MM.
    J Hosp Infect; 2009 Aug 22; 72(4):368-70. PubMed ID: 19443079
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP).
    Marumo K, Komukai D, Hirose M, Nakamura H, Tanaka H, Ugajin K, Nagashima G, Yoshimura A.
    J Infect Chemother; 2013 Apr 22; 19(2):348-51. PubMed ID: 22872187
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration.
    Pastor M, Basas J, Vairo C, Gainza G, Moreno-Sastre M, Gomis X, Fleischer A, Palomino E, Bachiller D, Gutiérrez FB, Aguirre JJ, Esquisabel A, Igartua M, Gainza E, Hernandez RM, Gavaldà J, Pedraz JL.
    Nanomedicine; 2019 Jun 22; 18():101-111. PubMed ID: 30849549
    [Abstract] [Full Text] [Related]

  • 19. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.
    Islan GA, Tornello PC, Abraham GA, Duran N, Castro GR.
    Colloids Surf B Biointerfaces; 2016 Jul 01; 143():168-176. PubMed ID: 27003467
    [Abstract] [Full Text] [Related]

  • 20. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
    Soren O, Rineh A, Silva DG, Cai Y, Howlin RP, Allan RN, Feelisch M, Davies JC, Connett GJ, Faust SN, Kelso MJ, Webb JS.
    J Antimicrob Chemother; 2020 Jan 01; 75(1):117-125. PubMed ID: 31682251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.